Drugs / Iruplinalkib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06436885 | Feb 2024 → Dec 2025 | non-small cell lung carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05716126 | Apr → Dec 2020 | — | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07330076 | Jan 2026 → Dec 2030 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06282536 | Mar 2024 → Jun 2025 overdue | — | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04641754 | Mar 2019 → Dec 2020 | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04632758 | Jun 2019 → Dec 2024 | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iruplinalkib | “Iruplinalkib (WX-0593) is a new-generation, potent ALK tyrosine kinase inhibitor (TKI) that has been found to have systemic and central nervous system (CNS) efficacy in...” PMID 38280448 ↗ Jan 20245“Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT).” PMID 36829154 ↗ Feb 2023 |
| Known as | WX-0593 | “Iruplinalkib (WX-0593) is a new-generation, potent ALK tyrosine kinase inhibitor (TKI) that has been found to have systemic and central nervous system (CNS) efficacy in...” PMID 38280448 ↗ Jan 20242“Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor.” PMID 36829154 ↗ Feb 2023 “Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1” NCT05716126 ↗ |
| Action | Inhibit | “potent ALK tyrosine kinase inhibitor (TKI)” PMID 38280448 ↗ Jan 2024 |
| Route | Oral | “Patients received iruplinalkib 180 mg orally once daily for a 21-day cycle with a 7-day lead-in phase at 60 mg orally once daily.” PMID 36829154 ↗ Feb 2023 |
| Target | ALK | “potent ALK tyrosine kinase inhibitor (TKI)” PMID 38280448 ↗ Jan 2024 |